Turinabol 10 mg

• Turinabol 10 mg Tablets
• Brand: Magnus Pharmaceuticals
• Content: 100 tablets 10 mg
• Total Compound: 1,000 mg per box
• Manufactured in: Europe

Product Overview

Magnus Pharmaceuticals’ Turinabol (4-Chlorodehydromethyltestosterone) is a Dianabol-derived oral compound known for its high anabolic:low androgenic profile, minimal water retention, and non-aromatising structure. With a ~16-hour half-life and peak plasma levels ~1 hour post-ingestion, it supports twice-daily dosing in lean-mass research and strength-adaptation trials.

Turinabol’s 4-chloro guard reduces estrogenic activity while its 17-alkylation ensures oral bioavailability—though it introduces hepatic stress in prolonged use. Long detection windows ( 2 weeks) and WADA S1 classification make it a reliable positive-control compound in anti-doping validation research.

Key Research Highlights

Precise strength-gain profile with limited virilisation risk

Non-aromatising: no estrogenic side effects or water retention

PK-backed dosing: t 16 h, 10 mg twice daily

Lean-mass enhancement: improves nitrogen retention & red-cell mass

ISO-validated detection via M3/M4 LC-MS/MS metabolites

Suggested Laboratory Applications

Androgenic activity vs. aromatisation-free models

Muscle strength and body-recomposition studies

Doping-assay development (LC-MS/MS workflows)

HPTA suppression and recovery investigations

Technical Specifications

Detection Window

2 weeks (M3/M4 metabolites, LC-MS/MS)

Shelf Life

36 months · Store 25 °C

Pharmacology & Performance Data

Research Focus

Key Findings

Anabolic: Androgenic Index

~53 anabolic, ~0–6 androgenic (between Dianabol & Oxandrolone)

Half-life & Dosing

~16 h · 10 mg BID dosing keeps plasma active

Lean Mass & Strength Effects

Positive nitrogen balance, improved strength, low aromatisation

Erythropoietic Action

Hemoglobin & RBCs in short cycles

Water Retention

Minimal due to 4-chloro substitution

Documented Research Risks

Risk Area

Noted Effects

Hepatotoxicity

17- alkylation linked to cholestasis & liver enzyme elevation

Lipid Disruption

HDL / LDL; cardiovascular strain rises with dose and duration

CNS/Cardio Activity

BP, HR, aggression in rodent & athlete models

Doping Violation

Detected via WADA S1 banned list & long-term M3/M4 metabolites

Handling & Compliance Notice

FOR RESEARCH USE ONLY.Not intended for human or veterinary administration. Purchase confirms qualified-researcher status and acceptance of all handling and liability protocols. Any exposure will trigger a positive anti-doping result.